Lantheus Holdings Company Profile (NASDAQ:LNTH)

Lantheus Holdings trades on the NASDAQ under the ticker symbol "LNTH."

Lantheus Holdings, Inc. (NASDAQ:LNTH) announced its quarterly earnings data on Tuesday, August, 1st. The company reported $0.42 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.24 by $0.18. The firm had revenue of $88.83 million for the quarter, compared to the consensus estimate of $80.56 million. Lantheus Holdings had a net margin of 8.44% and a negative return on equity of 37.47%. The business's revenue for the quarter was up 13.9% on a year-over-year basis. During the same period in the prior year, the company posted $0.24 earnings per share. View Lantheus Holdings' Earnings History.

Lantheus Holdings is scheduled to release their next quarterly earnings announcement on Monday, October, 30th 2017. View Earnings Estimates for Lantheus Holdings.

4 brokers have issued twelve-month target prices for Lantheus Holdings' stock. Their predictions range from $12.00 to $22.00. On average, they anticipate Lantheus Holdings' stock price to reach $18.75 in the next twelve months. View Analyst Ratings for Lantheus Holdings.

Lantheus Holdings saw a decrease in short interest in July. As of July 14th, there was short interest totalling 1,995,785 shares, a decrease of 28.1% from the June 30th total of 2,777,673 shares. Based on an average daily trading volume, of 630,798 shares, the days-to-cover ratio is presently 3.2 days. Approximately 7.2% of the company's shares are short sold.

Some companies that are related to Lantheus Holdings include Esperion Therapeutics (ESPR), Global Blood Therapeutics (GBT), Medpace Holdings (MEDP), Accelerate Diagnostics (AXDX), OraSure Technologies (OSUR), Momenta Pharmaceuticals (MNTA), LHC Group (LHCG), BioTelemetry (BEAT), Forward Pharma A/S (FWP), Natus Medical Incorporated (BABY), VAREX IMAGING (VREX), Quidel Corporation (QDEL), ABAXIS (ABAX), Genomic Health (GHDX), K2M Group Holdings (KTWO), The Ensign Group (ENSG), Irhythm Tech (IRTC) and NeuroDerm (NDRM).

Lantheus Holdings' management team includes the folowing people:

• Mary Anne Heino, President, Chief Executive Officer, Director
• John W. Crowley, Chief Financial Officer, Treasurer
• Michael P. Duffy, Senior Vice President, Strategy and Business Development, General Counsel and Secretary
• Timothy Healey, Senior Vice President, Commercial
• William C. Dawes JR, Vice President - Manufacturing and Operations
• Carol Walker, Vice President, Quality
• Simon Robinson, Vice President - Research & Pharmaceutical Development
• Cesare Orlandi M.D., Chief Medical Officer
• Brian A. Markison, Non-Executive Independent Chairman
• David F. Burgstahler, Director

(LNTH) raised $75 million in an initial public offering on Thursday, June 25th 2015. The company issued 7,900,000 shares at a price of $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Baird was co-manager.

Lantheus Holdings' stock is owned by a number of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.96%), Numeric Investors LLC (3.49%), Acadian Asset Management LLC (3.33%), Marshall Wace North America L.P. (2.83%), Feinberg Stephen (2.36%) and Renaissance Technologies LLC (1.85%). Company insiders that own Lantheus Holdings stock include Avista Capital Partners Gp, Ll, David F Burgstahler, Derace L Schaffer, Mary Anne Heino and Michael P Duffy. View Institutional Ownership Trends for Lantheus Holdings.

Lantheus Holdings' stock was sold by a variety of institutional investors in the last quarter, including Feinberg Stephen, Partners Group Holding AG, Numeric Investors LLC, Laurion Capital Management LP, GSA Capital Partners LLP, ClariVest Asset Management LLC, Acadian Asset Management LLC and OxFORD Asset Management LLP. Company insiders that have sold Lantheus Holdings stock in the last year include Avista Capital Partners Gp, Ll, David F Burgstahler, Derace L Schaffer, Mary Anne Heino and Michael P Duffy. View Insider Buying and Selling for Lantheus Holdings.

Lantheus Holdings' stock was bought by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Vanguard Group Inc., State Street Corp, Ameriprise Financial Inc., JPMorgan Chase & Co., Boston Advisors LLC, Castleark Management LLC and Bank of New York Mellon Corp. View Insider Buying and Selling for Lantheus Holdings.

Shares of Lantheus Holdings can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Lantheus Holdings stock can currently be purchased for approximately $15.70.